The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).
Allyson J. Ocean
No relevant relationships to disclose
Tanios S. Bekaii-Saab
Research Funding - Oncolytics Biotech
Imran Chaudhary
No relevant relationships to disclose
Romae Palmer
No relevant relationships to disclose
Paul J. Christos
No relevant relationships to disclose
Alice Mercado
No relevant relationships to disclose
Erika O. Florendo
No relevant relationships to disclose
Veronica A. Rosales
No relevant relationships to disclose
Joseph T. Ruggiero
No relevant relationships to disclose
Elizabeta C. Popa
No relevant relationships to disclose
Melissa Wilson
No relevant relationships to disclose
Mohammad Haroon Ghalib
No relevant relationships to disclose
Yijuan Hou
No relevant relationships to disclose
Umang Shah
No relevant relationships to disclose
Lakshmi Rajdev
No relevant relationships to disclose
Tarek Elrafei
No relevant relationships to disclose
George M. Gill
Employment or Leadership Position - Oncolytics Biotech
Stock Ownership - Oncolytics Biotech
Matthew C. Coffey
Employment or Leadership Position - Oncolytics Biotech
Stock Ownership - Oncolytics Biotech
Manish A. Shah
No relevant relationships to disclose
Sanjay Goel
Research Funding - Oncolytics Biotech